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cDNAs coding for the two receptor subunits of the interleukin-6 receptor have been stably expressed in Madine Darby canine kidney (MDCK) 
cells. The fate of the IL-6 binding protein (IL-6R) and of the signal transducing protein gpl30 was studied independently. Both proteins were 
proteolytically cleaved from cells metabolically labeled with [3”S]methionine/cysteine leading to the release of soluble receptor proteins of 55 kDa 
and 100 kDa, respectively. In contrast to the shedding of the ILdR gp130 was inefficiently released from the cells and the process was not 
significantly stimulated by the phorbolester PMA. In addition we show that the soluble forms of the IL-6R and gp130 released by transfected cells 
can form a ternary complexe with interleukin-6 indicating that such complexes also may occur in vivo. 
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1. I~RQD~CTION 
Interleukin-6 (IL-6) is a multifunctional cytokine in- 
volved in the regulation of the immune response, hema- 
topoiesis and acute phase response [l-5]. It has recently 
been recognized to be a member of the &-helical cyto- 
kine family [6]. IL-6 shares its activities with leukemia 
inhibitory factor (LIF) [7], oncostatin M (OSM) [S], 
interleukin-1  (IL-l 1) [9], and ciliary neurotrophic fac- 
tor (CNTF) [lo]. 
IL-6 exerts its action via cell surface receptor which 
consists of two subunits, an 80 kDa ligand binding pro- 
tein (ILdR) and a glycoprotein of 130 kDa (gp130) 
which is essential for the generation of an intracellular 
signal. Both proteins belong to the family of hemopoi- 
etic receptors characterized by conserved cysteines and 
a Trp-Ser-X-Trp-Ser motif in the extracellular part of 
the receptor proteins [ll]. Interestingly the cytokines 
LIF, OSM, IL-1 1 and CNTF also use the gp130 protein 
for signaling which may explain their overlapping bio- 
logical activities [12-17,261. 
Many if not all cytokine receptors have been de- 
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scribed to exist not only as membrane-bound but also 
as soluble forms which can be generated by two distinct 
mechanisms. Soluble receptors for IL-4, IL-7 and gran- 
ulocyte macrophage colony stimulating factor (GM- 
CSF) are translated from differentially spliced mRNAs 
[l S-201 whereas the soluble receptors for IL-l, tumor 
necrosis factor (TNT;), and nerve growth factor (NGF) 
are produced by limited proteolysis of the membrane- 
bound receptors (_21,22]. We have recently shown that 
a soluble form of the IL-6R is generated by shedding 
and that this process is regulated by PKC [23,24]. 
For the soluble form of the IL-6R and for a geneti- 
cally engineered form of the soluble CNTF receptor it 
has been shown that in the presence of the ligand they 
act agonistically on cells expressing the signal transduc- 
ing receptor subunit gp130 [25-281. This fact raises the 
important question whether also the gp130 receptor 
subunit is released from the cell. Quantitative shedding 
of gpl30 would lead to a cell which is not responsive to 
the cytokines IL-6, IL- 11, LIF, OSM and CNTF. 
Here we show that the second subunit of the inter- 
let&in-6 receptor, the signal transducer gp130, is re- 
leased from the cell as a 100 kDa soluble protein. The 
extent of shedding of gpl30, however, is almost negligi- 
ble when compared with shedding of the IL-6R. Fur- 
thermore we demonstrate that shedding of gpl30 is not 
significantly induced by PMA suggesting that the proc- 
ess is not regulated by PKC. IL-6 and the soluble forms 
of gpl30 and the IL-6R released by the cell form a 
complex suggesting that such complexes can occur in 
body fluids in vivo. Indeed, soluble gp130 has recently 
been detected in human serum [29]. 
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2. MATERIALS AND METHODS 
2.1. Reagents 
Restriction enzymes, calf intestinal phosphatase, T4-DNA ligate. 
and protease inhibitors were purchased from Boehringer Mannheim 
(Mannheim, Germany). Tra@S]label (44 TBq/mmol) was obtained 
from ICN (Meckenheim, Germany). DMEM was from GIBCO 
(Eggenstein, Germany). Recombinant human (rh) IL-6 was prepared 
as described by Arcone et al. [30]. The specific activity was 1.5 x lo6 
B-cell stimulatory factor 2 unitslmg protein [31]. The IL-6R-cDNA 
was isolated as described [32]. The polyclonal monospecific antiserum 
against he IL-6R was prepared by injecting the extracellular domain 
of the IL-6R expressed in E. coli into rabbits [33]. Culture supematants 
from transfected COS-7 cells containing soluble IL-6R have been 
described [23]. The generation and characterization of monoclonal 
antibodies against human gpl30 are described in [34]. Rhodamine 
conjugated anti mouse IgG antibody was obtained from Dakopats 
(Hamburg, Germany). 
B 
Wnca 
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2.2. Cell Cultures 
MDCK cells were grown in DMEM at 5% CO2 in a water saturated 
atmosphere. All cell culture media were supplemented with 10% fetal 
calf serum (Seromed, Berlin, Germany), streptomycin (100 mg/l) and 
penicillin (60 mg/l). 
2.3. Construction of expression plasmiah and transfection of cells 
The construction of the ILdR expression vector pExIR1 has been 
described [35]. The human gpl30 expression vector pZipNeol30BAS 
Fig. 1. Expression of the IL-6R and gpl30 in MDCK cells. (A) Sche- 
has been used by Hibi et al. [26]. Transfections were carried out as 
matic representation of the two interleukind receptor subunits ex- 
described [36] using the calcium-phosphate precipitation method [371. 
pressed in transfected MDCK cells. The black box represents the 
Cell clones stably expressing the ILdR or gpl30 were selected in the 
transmembrane domain. (B) Expression of the IC6R on MDCK cells 
presence of 500 pg/ml G418 and analyzed by Northern blotting [38] 
(MDCKgp80, left) and of gpl30 on MDCK (MDCKgpl30, right) 
and immunofluorescence. Expression of the IL-6R was induced by 
was assayed by indirect immunofluorescence staining using an ILdR 
stimulation of transfected MDCK cells with 100 PM ZnCl, for 8-12 
or gpl30 specific antibody, respectively, followed by rhodamine conju- 
h. 
gated anti mouse IgG antibodies. As a control untransfected MDCK 
cells were treated with the same antibodies. A 240-fold magnification 
2.4. Immunoprecipitation of proteins 
was used to photograph the cells. 
Cells were metabolically labeled with [3sS]methionine/cysteine u der 
conditions indicated in the legends to figures. Cell lysis was performed 
in 10 mM Tris-HCl, pH 7.4,60 mM EDTA, 1% Nonidet P40 and 0.4% 
sodium deoxycholate in the presence of a standard cocktail of protease 
inhibitors (Boehringer Mannheim). Cell lysates and media were pre- 
treated with pansorbin (Calbiochem, La Jolla, CA). SDS was added 
to a final concentration of 0.3%, Nonidet P40 to a final concentration 
of 1%. Subsequently cell lysates and media were incubated with the 
appropriate antibodies for 2 h at 4°C. The immune complexes were 
precipitated with protein A-Sepharose, separated on 10% SDS PAGE 
[39] and visualized by fluorography [40]. Immunoprecipitation of IL- 
6/lL-6R/gpl30 complexes was performed in the absence of SDS at a 
final concentration of 0.5% Triton X-100. 
shows that surface as well as intracellular expression of 
the ILdR and gp130 on transfected MDCK cells could 
be detected by indirect immunofluorescence using anti- 
bodies directed against the IL-6R and gp130. 
2.5. Indirect immuno$uorescence 
Approximately 10’ MDCK cells grown on cover glasses for 24 h 
were fixed with 2% paraformaldehyde as described [23]. Cells were 
treated with a l/200 dilution of a mAb against he ILdR (MT18) or 
against gpl30 (AM64) for 20 min. Detection of the mAbs was carried 
out with a l/200 dilution of a rhodamineconjugated anti murine IgG 
antibody for 20 min. All buffers used contained 0.1% Triton X-100. 
Cover glasses were mounted on slides with moviol and analyzed using 
fluorescence microscopy. A 500-fold magnification was used to photo- 
graph the cells. 
3. RESULTS 
Since we wanted to compare shedding of both sub- 
units of the interkeukin-6 receptor (Fig. 1A) we stably 
transfected MDCK cells with expression plasmids cod- 
ing for the human ILdR and human gp130. Fig. 1B 
Cell lysates and media from transfected MDCK cells 
which had been metabolically labeled with a pulse of 
[35S]methionine/cysteine in the absence or presence of 
PMA were immunoprecipitated with antibodies di- 
rected against the IL-6R and gp130. As shown in Fig. 
2A the ILdR could not be immunoprecipitated from 
untransfected cells (lane 1). In transfected cells an 80 
kDa protein was immunoprecipitated from cell lysates 
but was undetectable in cells which had been treated 
with PMA. In the supernatants of the same cells a 55 
kDa protein could be immunoprecipitated with an IL- 
6R specific antiserum. The generation of this soluble 
form of the ILdR was strongly induced by the activator 
of PKC. Interestingly, after PMA treatment we repeat- 
edly observed a shift of the cell-associated IL-6R pro- 
tein to a higher molecular weight form. A possible ex- 
planation would be that a PKC-mediated phosphoryla- 
tion of IL-6R occurs (Fig. 2A, lanes 2 and 3). Interest- 
ingly, such a mobility shift is not observed when shed- 
ding of an ILdR protein devoid of the cytoplasmic 
domain is analyzed (J. Mtillberg, unpublished results). 
A protein of 130 kDa was immunoprecipitated from 
175 
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Fig. 2. Generation of soluble forms of the IL&R and gp130 by limited proteolysis. (A) Expression of the IL-6R in MDCK cells (MDCK-gp80) 
was stimulated by treatment with 100 PM &Cl, for 12 h. 2 x lo6 cells were labeled with SOpCi Tran[3sSpabeI in methioninelcysteine-free m dium 
for 2 h. After 1 h of chase cells were incubated with lo-’ M PMA for 1 h aa indicated in the figure. The IG6R was ~~op~ipi~t~ from cell 
lysates (lanes 2 and 3) and media (lanes 5 and 6) with an IL-6R specific antiserum and analyzed by SDS-PAGE and fluorography. Untransfected 
MDCK cells were used as a control (lanes 1 and 4). (I%) M~K-~l30 cells constitutively expressing pl30 were radioactively labeled and 
~~opr~pitated in the same way as described for MDCKgp80 cells in (A). Lanes 7-9 are identical with lanes 4-6 except hat they were exposed 
ten times longer. I~~op~pitations were performed with the gpl30 specific mAb AM64 Soluble gp130 is marked by an arrow. (C) 2 x 10’ 
MDCK-gp130 cells were labeled with 500 ,uCi Tran[3SS]label in methioninefcysteine-free m dium for 2 h. After 16 h of chase soluble gp130 protein 
was immunoprecipitated from aliquots of the conditioned medium using various mAbs against gp130: AM64 (lane l), GPX7 (lane 2) and GPZ35 
(lane 3). Soluble gp130 is marked by an arrow. Exposure time: (A) 48 h, (R) 48 h (lanes l-6) and 3 weeks (lanes 7-9), (C) 2 weeks. 
cells transfected with gp130 cDNA (Fig. 2B). A faint 
band of 100 kDa was detected when supernatants of the 
same cells were immunoprecipitated (Fig. 2B, lanes 5 
and 6). The fluorography shown in Fig. 2B, lanes 7-9 
is the same as the one in lanes 4-6 except that exposure 
time was ten times longer. In contrast to the PMA- 
induced release of a soluble form of the IL-6R , the 
generation of the 100 kDa soluble form of the gpl30 
protein was only slightly increased when transfected 
cells were treated with PMA (compare Fig. 2A, lanes 5 
and 6 and Fig. 2B, lanes 8 and 9). Since the protein 
which migrates above the soluble form of gp130 is also 
seen in untransfected cells and is not always observed 
(Fig. 2C), we believe that it is only unspecifically precip- 
itated. The soluble form of gp130 generated from trans- 
fected MDCK cells was immunoprecipitated with three 
different mAbs directed against gpl30. As shown in Fig. 
2C the same 100 kDa protein was recognized by all 
176 
mAbs indicating that the soluble 100 kDa protein is 
indeed a soluble form of gp130. 
Since both proteins, the IL-6R and gp130 were re- 
leased from cells by limited proteolysis we asked 
whether these soluble receptor proteins could form a 
complex in the presence of IL-6. Fig. 3 shows an exper- 
iment in which su~~a~n~ of meta~~c~ly labeled 
MDCK cells stably transfected with gp130 cDNA were 
immunoprecipitated with antibodies against gpl30, the 
IL6-R and IL-6 in the presence or absence of IL-6 and 
soluble ILdR. The mAb AM64 which is directed 
against the extracellular part of gp130 recognizes a 100 
kDa protein (lanes 1, 8 and 10). The same protein is 
coprecipitated with an IL-6R specific antiserum only in 
the presence of IL-6 and soluble IL-6R (compare lane 
2 and lanes 4 and 7). An IL-6 antiserum does not copre- 
cipitate the soluble gp130 (lanes 3, 5 and 6). This is in 
accordance with the fact that this antics neutralizes 
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Fig. 3. Formation of a ternary complex of IL-6 soluble IL-fiR and 
soluble gpl30.2 x 107 MDCK-gp130 cells were labeled with 500 ,uC~ 
Tran~5Sjlabel in methionine/cysteine-free m dium for 2 h and subse- 
quently chased for 16 h. To aliquots of labeled MDCKgpl30 culture 
medium 100 ng recombinant human IL-6 and 500 ng ~01uble IL*6R 
protein in conditioned cell culture medium were added as indicated in 
the figure. Immunopreoipitations were carried out using ant&&es 
against IL-6 (polyclonal antiserum), the IG6R (polyclonal antiserum) 
and gp130 (mAb AM64) as indicated in the figure. 
&&ogicdt effects of IL-6 (data not shown), Xn all co- 
pr~ipitations a protein of g0 kDa is recognized due to 
the uon stringent precipitation conditions (compare 
Fig. 2 and Fig.. 3; see Section 2). Since such a protein 
band is also seen when no antibody was used (lane 9) 
or when untransfected cells were analyzed (data not 
shown) co-precipitation could be explained by noa-spe- 
cific adsorption to protein A Sepharose. 
4. DISCUSSION 
We have previously shown that a soluble form of the 
IL-6R is generated by limited proteolysis and that this 
process is strongly induced by activation of cellular 
PKC 123,241. We investigated in this study whether this 
is also true for gpl30 the signal transducing subunit of 
the interleukin-6 receptor. 
Metabolically labeled MDCK cells transfected with 
a gpl30 expression vector release a 100 kDa soluble 
protein which is recognized by three different gpl30 
mAbs. The cytoplasmic domain plus the transmem- 
brane domain of gpl30 consist of 299 amino acids 
which when subtracted fom 130 kDa results in a protein 
size of around 100 kDa. This indicates that cleavage of 
the protein must have occured close to the membrane. 
The fact that we used a gp130 cDNA to transfect 
MDCK cells makes it unlikely that the soluble form of 
gpl30 we detected has been synthesized from an alter- 
natively spliced mRNA. We conclude that at least in 
MDCK cells the soluble form of the gpl30 protein is 
generated by limited proteolysis. The mechanism of the 
formation of the soluble gpl30 in vivo remains to be 
elucidated, The extent to which the soluble form of 
gpl30 is released is negligible when compared with the 
shedding of the IL&R, In addition, this process seems 
not to be regulated by PKC since it can not be induced 
by the addition of PMA. 
The gpl3O also serves as a signal transducing subunit 
of the receptors for IL-l 1 z LIF, CNTF and OSM. Shed- 
ding of gpl30 would render cells unresponsive to all 
these cytokines. In view of this fact it is not surprising 
that gpl30 is not qmurtitatively released from the mem- 
brane as has been shown for the IL-6R. It can, however, 
not been excluded that there are stimuli which lead to 
more efficient shedding of gp130. 
Genetically engineered soluble forms of the ILdR 
and gpl30 have been shown to form a complex in the 
presence of IL-6 [41]. Our finding that this is also true 
for the the soluble forms of the two interleukin-6 recep- 
tor subunits which are released by cells might have in- 
teresting implications. The soluble form of the IL-6R 
together with IL-6 initiates IL-6 specific signals on cells 
which only express gp130 on the cell surface, i.e. which 
do not by themselves bind IL-6. It can be speculated 
that the soluble form of gp130 might act as an antago- 
nist of soluble IL-6R/IL-6 complexes. The serum con- 
centrations of the IL-6R, gp130 and IL-6 and their af- 
finity constants will determine whether agonistic or an- 
tagonistic activities are obtained. Therefore it is of great 
interest that in a rwent study soluble gp130 has been 
detected in human serum and has been shown to form 
complexes with the soluble ILdR and IL-6 1291. Soluble 
gpl30 even seems to have the potential to inhibit signals 
through the membrane-anchored gpl30 signal 
transducing protein [29].It will be important to measure 
the exact concentrations of soluble IL-6R, gpl30 and 
IL-6 in body fluids in normal and i&lamed states and 
to determine the respective binding affinities. Only the 
~owl~ge of all these parameters will allow to under- 
stand and to predict biological effects of the cytokine 
IL-6. 
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